株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ニコチン中毒症:パイプライン製品の分析

Nicotine Addiction - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 245978
出版日 ページ情報 英文 57 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.96円で換算しております。
Back to Top
ニコチン中毒症:パイプライン製品の分析 Nicotine Addiction - Pipeline Review, H1 2017
出版日: 2017年03月15日 ページ情報: 英文 57 Pages
概要

ニコチン中毒症は、ニコチンへの薬物依存によって引き起こされるタバコ製品への依存症です。年齢、抑うつ傾向、統合失調症、PTSD、アルコール依存などの要因によって発病し、摂取中止の際には手の震え、発汗、神経過敏、心拍数の上昇などといった離脱症状がでる場合もあります。ニコチン置換療法などにより治療を行います。

当レポートでは、ニコチン中毒症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

ニコチン中毒症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ニコチン中毒症:企業で開発中の治療薬

ニコチン中毒症:大学/機関で研究中の治療薬

ニコチン中毒症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

ニコチン中毒症:企業で開発中の製品

ニコチン中毒症:大学/機関で研究中の製品

ニコチン中毒症の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International

ニコチン中毒症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ニコチン中毒症:最近のパイプライン動向

ニコチン中毒症:休止中のプロジェクト

ニコチン中毒症:開発が中止された製品

ニコチン中毒症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9063IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nicotine Addiction - Overview
  • Nicotine Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nicotine Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nicotine Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Astraea Therapeutics LLC
    • C4X Discovery Holdings PLC
    • Chronos Therapeutics Ltd
    • CV Sciences Inc
    • Hager Biosciences LLC
    • Heptares Therapeutics Ltd
    • Omeros Corp
    • Savant HWP Inc
  • Nicotine Addiction - Drug Profiles
    • (cannabidiol + nicotine bitartrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EORA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nicotine Addiction - Dormant Projects
  • Nicotine Addiction - Discontinued Products
  • Nicotine Addiction - Product Development Milestones
    • Featured News & Press Releases
      • May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development
      • Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
      • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
      • Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine
      • May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nicotine Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Nicotine Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
  • Nicotine Addiction - Pipeline by C4X Discovery Holdings PLC, H1 2017
  • Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H1 2017
  • Nicotine Addiction - Pipeline by CV Sciences Inc, H1 2017
  • Nicotine Addiction - Pipeline by Hager Biosciences LLC, H1 2017
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Nicotine Addiction - Pipeline by Omeros Corp, H1 2017
  • Nicotine Addiction - Pipeline by Savant HWP Inc, H1 2017
  • Nicotine Addiction - Dormant Projects, H1 2017
  • Nicotine Addiction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Nicotine Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top